A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas: A Study of the Mayo Phase 2 Consortium (P2C)

BACKGROUND: The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI-779), a mammalian target of rapamycin in patients with advanced soft tissue sarcomas (STS). METHODS: Patients ≥18 years with measurable advanced STS, no prior chemotherapy for metastatic disea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Okuno, Scott, Bailey, Howard, Mahoney, Michelle R., Adkins, Douglas, Maples, William, Fitch, Tom, Ettinger, David, Erlichman, Charles, Sarkaria, Jann N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3312920/
https://ncbi.nlm.nih.gov/pubmed/21287536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25928
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados